Clinically Important Meperidine Toxicities

REFERENCES

• Mitchell A, Fisher A P, Brunner M, et al. Pethidine for painful crisis in sickle cell disease. BMJ. 1991; 303: 249
   Google Scholar
• Clark R F, Wei E M, Anderson P O. Meperidine: therapeutic use and toxicity. J Emerg Med. 1995; 13(6)797–802
   Google Scholar
• Clinical Practice Guideline. Acute Pain Management: Operative or Medical Procedures and Trauma. Agency for Health Care Policy and Research Publication No. 92–0032. U.S. Dept. of Health and Human Services, Betehsda, MD 1992
   Google Scholar
• Clinical Practice Guideline. Management of Cancer Pain. Agency for Health Care Policy and Research Publication No. 94–0592. U.S. Dept. of Health and Human Services, Bethesda, MD 1994
   Google Scholar
• Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 4th edition. American Pain Society, Glenview, IL 1999
   Google Scholar
• Practice Guidelines for Cancer Pain Management. A Report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Anesthesiology. 1996; 84: 1243–57
   PubMedGoogle Scholar
• Reisine R, Pasternak G. Opioid analgesics and antagonists. The pharmacological basis of therapeutics (9th ed), J G Hardman, Le Limbird, P B Molinoff, R W Ruddon, A G Filman. Mcgraw-Hill;, New York 1996; 521–555
   Google Scholar
• Forman W B. Opioid analgesic drugs in the elderly. Clin Geriat Med. 1996; 12(3)489–500
   PubMedGoogle Scholar
• Kurz M, Belani K G, Sessler D, et al. Naloxone, meperidine and shivering. Anesthesiol. 1993; 79(6)193–1201
   Google Scholar
• Abbott Pharmaceuticals. Demerol package insert. North Chicago, IL August, 1997
   Google Scholar
• Tatro D S. Facts & Comparisons. Narcotic Analgesic Facts. Facts & Comparisons, St. Louis 2000; 784–9
   Google Scholar
• Baumann T J. Pharmacotherapy. Pain Management, 4th ed., DiPiro, et al. A Pathophysiological Approach., Connecticut, Appleton & Lange 1999
   Google Scholar
• Tatro D S, Safani M. Narcotic analgesics comparative review [drug consult]. Micromedex March, 1996
   Google Scholar
• Hassan H, Bastani B, Gellens M. Successful treatment of normeperidine neurotoxicity by hemodialysis. Am J Kidney Dis. 2000; 35(1)146–149
   Google Scholar
• Szeto H H, Inturrisi C E, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Int Med. 1977; 86: 738–741
   PubMed Web of Science ®Google Scholar
• Shug S A, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Safety. 1992; 7(3)200–213
   Google Scholar
• Flacke J W, Flacke W E, Bloor B C, et al. Histamine release by four narcotics: a double-blind study in humans. Anesth Analg. 1987; 66(8)723–730
   Google Scholar
• Righard L, Alade M O. Effect of delivery room routines on the success of first breast-feed. Lancet. 1990; 336: 105–1107
   Google Scholar
• Wittels B, Scott D T, Sinatra R S. Exogenous opioids in human breast milk and acute neonatal neurobehavior: a preliminary study. Anesthesiology. 1990; 73(5)864–869
   PubMed Web of Science ®Google Scholar
• Helm J F, Venu R P, Geenen J E, et al. Effects of morphine on the human sphincter of Oddi. Gut. 1988; 29: 1402–1407
   PubMed Web of Science ®Google Scholar
• Sherman S, Lehman G A. Opioids at the sphincter of Oddi. Gastrointest Endos. 1994; 40(1)105–106
   Google Scholar
• Staritz M, Poralla T, Manns M, et al. Effect of modern analgesic drugs (tramadol, pentazocine, and buprenorphine) on the bile duct sphincter in man. Gut. 1986; 27: 567–569
   PubMed Web of Science ®Google Scholar
• Krimmer H, Bullingham R E, Lloyd J, et al. Effects on biliary tract pressure in humans of intravenous ketorolac tromethamine compared with morphine and placebo. Anesth Analagesia. 1992; 75: 204–207
   Google Scholar
• Bowdle T A. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. Drug Safety. 1998; 19(3)173–189
   Google Scholar
• Vanderhoff B T, Mosser K H. Jimsonweed toxicity: management of anticholincergic plant ingestion. Am Fam Phys. 1992; 46(2)526–530
   Google Scholar
• Lyons B, Carroll M, McDonald N J. The treatment of postanaesthetic shivering: a double blind comparison between alfentanil and pethidine. Acta Anaesthesiol Scand. 1995; 39: 979–982
   Google Scholar
• Pauca A L, Savage R T, Simpson S, et al. Effect of pethidine, fentanyl and morphine on postoperative shivering in man. Acta Anaesthesiol Scand. 1984; 28: 138–143
   PubMed Web of Science ®Google Scholar
• Burks L C, Aisner J, Fortner C L, et al. Meperidine for the treatment of shaking chills and fever. Arch Intern Med. 1980; 140: 483–484
   PubMedGoogle Scholar
• Oldfield E C, Burnett R J, Reents S B. Meperidine for prevention of amphotericin B-induced chills. Clin Pharm. 1990; 9: 251–252
   PubMedGoogle Scholar
• Rosa G, Dell'Utri D, Conti G, et al. Efficacy of nefopam for the prevention and treatment of amphotericin B-induced shivering. Arch Intern Med. 1997; 157: 1589–1592
   Google Scholar
• Vogelsang J, Hayes S R. Butorphanol tatrate (Stadol) relieves postanesthetic shaking more effectively than meperidine (Demerol) or morphine. J Post Anesth Nurs. Apr, 1992; 7(2)94–100
   Google Scholar
• Jejuna M, Ackerman W, Hein M F, et al. Butorphanol for the relief of shivering associated with extradural anesthesia in patients. J Clin Anesth. 1992; 4(5)390–339
   Google Scholar
• Goetting M G, Thirman M J. Neurotoxicity of meperidine. Ann Emerg Med. 1985; 14: 1007–1009
   PubMed Web of Science ®Google Scholar
• Smith M T. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exper Pharmacol Physiol. 2000; 27: 524–528
   PubMed Web of Science ®Google Scholar
• Potter J M, Reid D B, Shaw R J, et al. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ. 1989; 299: 150–153
   PubMedGoogle Scholar
• Babul N, Darke A C. Putative role of hydromorphone metabolites in myoclonus. Pain. 1992; 51: 260–261
   PubMed Web of Science ®Google Scholar
• Gregory R E, Grossman S, Sheidler V R. Grand-mal seizures associated with high-dose intravenous morphine infusions: incidence and possible etiology. Pain. 1992; 51(2)255–258
   Google Scholar
• Meisel S B, Wilfor P K. Seizures associated with high-dose intravenous morphine containing sodium bisulfite preservative. Ann Pharmacother. 1992; 26(12)1515–1517
   Google Scholar
• Daeninck P J, Bruera E. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity?. Acta Anaesthes Scand. 1999; 43: 924–938
   PubMed Web of Science ®Google Scholar
• Potter J M, Reid D B, Shaw R J, et al. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ. 1989; 299: 150–153
   PubMedGoogle Scholar
• Jayawarden B, Hill D J. Myoclonic spasms after epidural diamorphine infusion. Anaesthesia. 1991; 46(6)473–474
   Google Scholar
• Glavina M J, Robertshaw R. Myoclonic spasms following intrathecal morphine. Anaesthesia. 1988; 43(5)389–390
   Google Scholar
• Parkinson S K, Bailey S L, Little W L, et al. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology. 1990; 72(4)743–745
   PubMedGoogle Scholar
• Landow L. An apparent seizure following inadvertent intrathecal morphine. Anesthesiology. 1985; 62(4)545–546
   Google Scholar
• Kloke M, Bingel U, Seeber S. Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking. Support Care Cancer. 1994; 2(4)249–252
   Google Scholar
• Stambaugh J E, Winer I W, Santead J K, et al. The clinical pharmacology of meperidine. J Clin Pharmacol 1976; 16: 245–256
   PubMed Web of Science ®Google Scholar
• Hagmeyer K O, Mauro L S, Mauro V F. Meperidine-related seizures associated with patient controlled analgesia pumps. Ann Pharmacother. 1993; 27: 29–32
   Google Scholar
• Hochman M S. Meperidine-associated myoclonus and seizers in long-term hemodialysis patients. Ann Neurol. 1983; 14(5)593
   Google Scholar
• Kaiko R F, Foley K M, Grabinski P Y, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol. 1983; 13: 180–185
   PubMed Web of Science ®Google Scholar
• Pryle B J, Grech H, Stoddart P A, et al. Toxicity of norpethidine in sickle cell crisis. BMJ. 1992; 304: 1478–1479
   PubMedGoogle Scholar
• Rodman D P, Maxwell A J. Meperidine-induced seizure in a sickle cell patient using a patient controlled analgesia pump. J Am Board Fam Pract. 1994; 7(6)520–522
   Google Scholar
• Reutens D C, Stewart Wynne E G. Norpethidine induced myoclonus in a patient with renal failure. J Neurol Neurosurg Psychiatry. 1989; 52(12)1450–1451
   Google Scholar
• Tang R, Shimomura S K, Rotblatt M. Meperidine-induced seizures in sickle cell patients. Hosp Formul. 1980; 15: 764–772
   Google Scholar
• Stone P A, Macintyre P E, Jarvis D A. Norpethidine toxicity and patient controlled analgesia. Br J Anaesth. 1993; 71: 738–740
   PubMed Web of Science ®Google Scholar
• Kyff J V, Rice T L. Meperidine-associated seizures in a child. Clin Pharm. 1990; 9: 337–338
   PubMedGoogle Scholar
• Marinella M A. Meperidine-induced generalized seizures with normal renal function. South Med J. 1997; 90(5)556–557
   Google Scholar
• Morisy L, Platt D. Hazards of high-dose meperidine. JAMA. 1986; 255(4)466–467
   Google Scholar
• Mauro V F, Bonfilio M F, Spunt A L. Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia. Clin Pharm. 1986; 5: 837–839
   Google Scholar
• Eisendrath S J, Goldman B, Douglas J, et al. Meperidine-induced delirium. Am J Psych. 1987; 144(8)1062–1065
   Google Scholar
• Fogarty T, Murray G B. Psychiatric presentation of meperidine toxicity. J Clin Psychopharm. 1987; 7(2)116–117
   Google Scholar
• Crawford R D, Baskoff J D. Fentanyl associated delirium in man. Anesthesiol. 1980; 53: 168–169
   PubMedGoogle Scholar
• Bruera E, Schoeller T, Montejo G. Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain. 1992; 48: 397–399
   PubMed Web of Science ®Google Scholar
• Lehmann K A. Opioids: overview on action, interaction and toxicity. Support Care Cancer. 1997; 5: 439–444
   Google Scholar
• Mercandante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999; 86(9)1856–1866
   Google Scholar
• Lieberman A N, Goldstein M. Reversible parkinsonism related to meperidine. N Engl J Med. 1985; 312(8)509
   Google Scholar
• Olive J M, Masana L, Gonzolez J. Meperidine and reversible parkinsonism. Mov Disord. 1994; 9(1)115–116
   Google Scholar
• Ross R T. Drug-induced parkinsonism and other movement disorders. Can J Neurol Sci. 1990; 17(2)155–162
   PubMed Web of Science ®Google Scholar
• Sporer A. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Safety. 1995; 13(2)94–104
   Google Scholar
• Weiner A. Meperidine as a potential cause of serotonin syndrome in the emergency department. Acad Emerg Med. 1999; 6(2)156–158
   Google Scholar
• Hansten P D, Horn J T. Hansten and Horn's Drug Interactions Analysis and Management. Facts and Comparisons., St. Louis, MO 2000; 378–379, 147
   Google Scholar
• Drug Interaction Facts, D S Tatro. Facts and Comparisons., St. Louis, MO 1997
   Google Scholar